听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览CURRENT PHARMACEUTICAL DESIGN期刊下所有文献
  • Drugs acting on DNA topoisomerases: recent advances and future perspectives.

    abstract::DNA-topoisomerases, a family of DNA-processing enzymes, represent the pharmacological target of major clinically useful chemotherapeutic agents. These drugs essentially act by trapping a topoisomerase-DNA cleavable complex, an intermediate in the enzyme s catalytic cycle. Research activity in this field continues to g...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Gatto B,Capranico G,Palumbo M

    更新日期:1999-03-01 00:00:00

  • Therapeutic strategies for coronary artery disease beyond low density lipoprotein (LDL)--lowering.

    abstract::Coronary artery disease (CAD) ranks as the leading cause of death in the Western world. The most widely used therapeutics utilized for the treatment of CAD are the lipid-lowering drugs, which lower plasma cholesterol. However lowering cholesterol alone may not be sufficient to provide benefit to all patient population...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Arad Y,Saxena U

    更新日期:1999-01-01 00:00:00

  • Inhibitors of tryptase for the treatment of mast cell-mediated diseases.

    abstract::Human tryptase is a structurally unique and mast cell specific trypsin-like serine protease. Recent biological and immunological investigations have implicated tryptase as a mediator in the pathology of numerous allergic and inflammatory conditions including rhinitis, conjunctivitis, and most notably asthma. A growing...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Rice KD,Tanaka RD,Katz BA,Numerof RP,Moore WR

    更新日期:1998-10-01 00:00:00

  • A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer.

    abstract::Doxorubicin has been a constituent of antitumor drug protocols for a broad spectrum of cancers for more than two decades. Side effects and resistance continue to be important limitations. Drug targets responsible for both side effects and anti-tumor activity are cell membrane receptors, cell membrane lipids, nucleic a...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Taatjes DJ,Fenick DJ,Gaudiano G,Koch TH

    更新日期:1998-06-01 00:00:00

  • Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM?

    abstract::Inhibition of fatty acid oxidation is well recognized as a potentially effective mechanism for controlling glycemia in non-insulin-dependent diabetes mellitus (NIDDM). However, a direct targeting of inhibition of the intramitochondrial beta-oxidation pathway or an indirect modulation of fatty acid oxidation by inhibit...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Anderson RC

    更新日期:1998-02-01 00:00:00

845 条记录 22/22 页 « 12...141516171819202122 »